Industry Colloquium: The Future of Liver Preservation: Perspectives, Advances and Perfusion Device Workshop

Alexandria, VA – Registration is now open for the American Association for the Study of Liver Diseases’ (AASLD) 2022 Industry Colloquium: Perspectives and Advances in Liver Preservation on November 3 in Washington, DC. New advances around perfusion devices are changing the game by keeping transplant livers alive longer, allowing for transportation of longer distances. New technology also enhances

NAFLD Nomenclature Consensus Meeting High-Level Output

The 2-day meeting in Chicago on 8-9 July 2022 convened 129 consensus survey participants in person or online. The participants originated from 32 countries, representing multiple societies including AASLD, EASL, APASL, ALEH, AGA and UEG, patients and patient advocacy organizations, regulators and industry representatives. View the NAFLD Nomenclature Consensus Meeting High-Level Output in Spanish

AASLD Foundation Funds Over $1.5 Million in Hepatology Research and Career Development in 2022

Alexandria, VA – The American Association for the Study of Liver Diseases (AASLD) Foundation, the largest medical society supporter of liver disease research and training in the United States, today announced its combined investment of over $1.5 million in Research and Career Development Awards, Abstract Awards, Emerging Liver Scholars (ELS) Program for medical residents and its new Emerging Liver

Guidance for Acute Hepatitis Outbreak in Children

July 14, 2022 Update The New England Journal of Medicine has recently published two new research articles on this issue, along with an editorial from AASLD Board Councilor and Future President, Saul Karpen, MD, Ph.D., FAASLD. Read the latest here: A Case Series of Children with Acute Hepatitis and Human Adenovirus Infection Clinical Spectrum of Children with Acute Hepatitis of Unknown Cause Read

AASLD Provides COVID-19 FAQs for Liver Transplant Recipients

It is difficult to know whether liver transplant recipients are at higher risk of severe disease, hospitalization, and death from COVID-19 compared to the general population. Case series and registry studies suggest that liver transplantation and immunosuppression do not lead to worse COVID-19 outcomes. However, the CDC has identified organ transplantation and immunosuppression as conditions that

CDC Health Advisory

The Centers for Disease Control and Prevention (CDC) has reported a cluster of children identified with acute hepatitis and adenovirus infection in Alabama, and similar reports have surfaced in the UK. Several have undergone liver transplantation, and none have died. All the children were previously healthy and an association between adenovirus and pediatric hepatitis is currently being

AASLD Announces New Class of Fellows

AASLD is pleased to announce the selection of twenty-four hepatology leaders as Fellows and one allied health leader focused on hepatology as an Associate Fellow. The Fellows Programs bestows honorary recognition upon AASLD members who have made a significant contribution to the knowledge and/or practice of liver and biliary diseases, and are considered leaders in the field. AASLD Fellows and

AASLD 2022 Capitol Hill Day Recap

On March 23, AASLD held its annual Liver Capitol Hill Day. For the third time since the beginning of the COVID-19 pandemic, this year’s LCHD was conducted online. Bringing together 45 participants, including AASLD members, patient advocates, Emerging Liver Scholars, and society staff. Participants joined 53 meaningful conversations on AASLD’s priorities with members of Congress and their staff

GI Societies Vote No On ANSI/AAMI Revisions On Endoscopic Processing

Changes to ST91 for Flexible and Semi-Rigid Endoscopes Create Obstacles to Implement Standards and Offer Impractical, Inappropriate or Conflicting Guidance AASLD, ACG, AGA, ASCRS, ASGE, SAGES and SGNA are committed to initiatives focused on eliminating healthcare-associated infections through improved education about evidence-based practices. While our societies appreciated the opportunity to

Coming Soon: New Funding Program for Early-Career APPs from AASLD Foundation

A new program for early career and new-to-hepatology Advanced Practice Providers will launch this spring with the goal of strengthening the liver provider pipeline and fostering the next generation of APP leaders in hepatology. “Since 2004, AASLD Foundation (originally through AASLD) has provided over $10.4 million to support APP specialized training through the NP/PA Clinical Hepatology

In Memoriam - Dr. Joseph (Joe) R. Bloomer, MD, FACP, FAASLD

AASLD acknowledges the passing of esteemed member and fellow, Joseph R. Bloomer, MD, FACP, FAASLD. Dr. Bloomer was a distinguished physician-scientist and leader in the study of liver disease. He passed away on December 22, 2021, from complications related to Alzheimer's Disease. A widely acclaimed teacher, accomplished researcher, and compassionate clinician, Dr. Bloomer was Director of the UAB

Dr. DeLeve President's Welcome

For those of you who may not know me, I’m Laurie DeLeve, AASLD’s 73rd president. Once upon a very long time ago, my then-toddler told her teacher I am a mouse doctor. I am a physician-scientist doing basic research at USC. More importantly, since 1997, except for one single year, I have always been on an at least one AASLD committee, SIG or in a leadership position. I love the spirit, camaraderie

Reaching Consensus on NAFLD Nomenclature

There has been much progress regarding the ongoing discussions over nomenclature for nonalcoholic fatty liver disease (NAFLD). AASLD has been leading and participating in a global multi-stakeholder process that includes extensive involvement from patient groups to examine the options and ramifications around nomenclature in this condition. This nomenclature task force includes representatives from

AASLD Leaders Go To Washington (Virtually)

Often in this space, we discuss the advocacy efforts of AASLD with regard to the Congress, focusing on important authorizing and funding legislation pending and our efforts to advance it for the benefit of liver patients and AASLD members. But enacting laws in only one part of the equation. Those laws must be implemented, which is the responsibility of the Executive Branch. During December and